The Experts below are selected from a list of 45552 Experts worldwide ranked by ideXlab platform
Nicolai F Myasoedov - One of the best experts on this subject based on the ideXlab platform.
-
cell metabolism of acyclovir phosphonate derivatives and antiherpesvirus activity of their combinations with Alpha2 Interferon
Chemical Biology & Drug Design, 2007Co-Authors: Yuri S Skoblov, Inna L Karpenko, Maxim V Jasko, M K Kukhanova, Valery L Andronova, G A Galegov, G V Sidorov, Nicolai F MyasoedovAbstract:The combinational use of acyclovir (ACV) phosphonate esters and alpha(2)-Interferon was shown to produce a synergistic effect on inhibition of HSV-1 replication in Vero cell cultures. Unlike other acyclovir phosphonate derivatives studied earlier, ACV H-phosphonate is not an ACV prodrug. On penetrating into the cells, it may be directly converted into ACV monophosphate escaping dephosphonylation-phosphorylation steps.
Yuri S Skoblov - One of the best experts on this subject based on the ideXlab platform.
-
cell metabolism of acyclovir phosphonate derivatives and antiherpesvirus activity of their combinations with Alpha2 Interferon
Chemical Biology & Drug Design, 2007Co-Authors: Yuri S Skoblov, Inna L Karpenko, Maxim V Jasko, M K Kukhanova, Valery L Andronova, G A Galegov, G V Sidorov, Nicolai F MyasoedovAbstract:The combinational use of acyclovir (ACV) phosphonate esters and alpha(2)-Interferon was shown to produce a synergistic effect on inhibition of HSV-1 replication in Vero cell cultures. Unlike other acyclovir phosphonate derivatives studied earlier, ACV H-phosphonate is not an ACV prodrug. On penetrating into the cells, it may be directly converted into ACV monophosphate escaping dephosphonylation-phosphorylation steps.
M Mauritsas - One of the best experts on this subject based on the ideXlab platform.
-
use of recombinant Alpha2 Interferon in combination with myelosan for the treatment of patients with chronic myeloid leukemia
Gematologiia i transfuziologiia, 1996Co-Authors: V I Petukhov, I L Strozha, D K Bondare, Ia G Feldmane, M MauritsasAbstract:The authors present results of chronic myeloid leukemia (CML) treatment with recombinant and leukocytic Interferon in monotherapy and in combination with myelosan. The best responses (72% of complete hematological remissions) were obtained in patients pretreated with myelosan (one course of 1-1.5 months) in combination with natural antioxidants.
Martin M Oken - One of the best experts on this subject based on the ideXlab platform.
-
phase ii study of Alpha2 Interferon in the treatment of the chronic myeloproliferative disorders e5487 a trial of the eastern cooperative oncology group
Cancer, 2003Co-Authors: I Arthur M D Radin, Haesook T Kim, W Barbara M D Grant, M John M D Bennett, M John M D Kirkwood, A James M D Stewart, G Richard M D Hahn, P Janice M D Dutcher, H Peter M D Wiernik, Martin M OkenAbstract:BACKGROUND In vitro and clinical data suggest a therapeutic role for α2 Interferon (IFN) in the treatment of the chronic myeloproliferative disorders. Accordingly, a multiinstitutional, Phase II trial of IFN in patients with agnogenic myeloid metaplasia (AMM), essential thrombocythemia (ET), and polycythemia rubra vera (PRV) in the spent phase was initiated. The objectives of this study were 1) to investigate the response rates that may be achieved with IFN in the treatment of patients with these disorders, 2) to estimate the durability of the responses, and 3) to assess the toxicities of IFN in these populations. METHODS Enrollment was limited to patients with AMM, ET, or PRV who already had developed 1) anemia or transfusion dependency, 2) thrombocytosis uncontrolled by standard therapy, 3) hemostatic complications, or 4) symptomatic splenomegaly. Initially, patients were started on IFN at a dose of 5 MU/m2 per day as a subcutaneous injection. After the first 16 patients had been treated, the starting dose of IFN was reduced to 2 MU/m2 per day because of unexpected toxicities. RESULTS IFN demonstrated different levels of efficacy and toxicity in each of the three diseases studied. The overall response rates achieved among the evaluable patients in each category were as follows: ET, 88.2% (n = 17 patients; 1 complete response and 14 partial responses); PRV, 41.7% (n = 12 patients; 1 complete response and 4 partial responses); and AMM, 3.2% (n = 31 patients; 0 complete responses and 1 partial response). Thrombocytosis and leukocytosis were controlled in nearly all patients, with reversal of splenomegaly and resorption of myelofibrosis achieved in fewer patients. The toxicities attributed to IFN differed notably among the three disease groups: patients who had AMM suffered systemic and neurologic toxicities more frequently than patients who had PRV or ET; whereas patients who had ET experienced a greater than expected incidence of hepatic abnormalities, most typically transient elevations of serum amino acid transaminase levels. CONCLUSIONS The current study demonstrated the safety and efficacy of IFN in patients with ET, PRV, and AMM. Objective responses and/or disease stabilization were obtained in patients with all three disease entities, including the reversal of splenomegaly and resorption of myelofibrosis in some patients. Cancer 2003;98:100–9. © 2003 American Cancer Society. DOI 10.1002/cncr.11486
Inna L Karpenko - One of the best experts on this subject based on the ideXlab platform.
-
cell metabolism of acyclovir phosphonate derivatives and antiherpesvirus activity of their combinations with Alpha2 Interferon
Chemical Biology & Drug Design, 2007Co-Authors: Yuri S Skoblov, Inna L Karpenko, Maxim V Jasko, M K Kukhanova, Valery L Andronova, G A Galegov, G V Sidorov, Nicolai F MyasoedovAbstract:The combinational use of acyclovir (ACV) phosphonate esters and alpha(2)-Interferon was shown to produce a synergistic effect on inhibition of HSV-1 replication in Vero cell cultures. Unlike other acyclovir phosphonate derivatives studied earlier, ACV H-phosphonate is not an ACV prodrug. On penetrating into the cells, it may be directly converted into ACV monophosphate escaping dephosphonylation-phosphorylation steps.